Preclinical in vivo studies have reported that increasing Wnt/β-catenin signaling by administering anti-DKK1 antibodies, Wnt3a, or LiCl suppresses MM-induced bone loss and MM cell growth [11-15]. This evidence concerns the gene WNT3A and Miyoshi myopathy.